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Abstract
Background
The epidemiology of Chikungunya virus (CHIKV) in the Middle East and North Africa
(MENA) is not well characterized despite increasing recognition of its expanding infection
and disease burden in recent years.
Methodology / Principal findings
Following Cochrane Collaboration guidelines and reporting our findings following PRISMA
guidelines, we systematically reviewed records describing the human prevalence and inci-
dence, CHIKV prevalence/infection rates in vectors, outbreaks, and reported cases for
CHIKV across the MENA region. We identified 29 human seroprevalence measures, one
human incidence study, one study reporting CHIKV infection rates in Aedes, and nine out-
breaks and case reports/series reported in the MENA from 1970–2015. Overall, anti-CHIKV
antibody or reports of autochthonous transmission were identified from 10 of 23 countries in
the MENA region (Djibouti, Egypt, Iraq, Iran, Kuwait, Pakistan, Saudi Arabia, Somalia,
Sudan, and Yemen), with seroprevalence measures among general populations (median
1.0%, range 0–43%) and acute febrile illness populations (median 9.8%, range 0–30%).
Sudan reported the highest number of studies (n = 11) and the highest seroprevalence
among general populations (median 12%, range 0–43%) and undifferentiated acute febrile
illness populations (median 18%, range 10–23%). CHIKV outbreaks were reported from Dji-
bouti, Pakistan, Sudan, and Yemen.
Conclusions / Significance
Seroprevalence studies and outbreak reports suggest endemic transmission of urban cycle
CHIKV in at least the Red Sea region and Pakistan. However, indications of seroprevalence
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CHIKV transmission is currently underrecognized.
Author summary
Chikungunya virus (CHIKV) is an alphavirus whose principal vectors are the Aedes aegypti
and Aedes albopictus mosquitoes. Though long endemic to Asia and Africa, detection of
CHIKV has recently been reported throughout the Western Hemisphere, including much
of South America and the Caribbean. In the Middle East and North Africa (MENA), the
epidemiology of CHIKV remains poorly characterized despite recent reports of outbreaks
and novel transmission in the Arabian Peninsula. To better understand existing data
describing the epidemiology of urban CHIKV in the MENA region, we conducted a sys-
tematic review of human prevalence studies and incidence studies; CHIKV detections,
prevalence, and infection rates in Aedes; and reported CHIKV outbreaks, case series, and
case reports from the region. A total of 29 seroprevalence studies were identified through
our search, with anti-CHIKV antibodies and/or outbreaks detected in Djibouti, Egypt,
Iraq, Iran, Kuwait, Pakistan, Saudi Arabia, Somalia, Sudan, and Yemen. Sudan reported
the highest number of studies (n = 11) and the highest seroprevalence among all studies.
The epidemiology of urban CHIKV in other MENA countries is less well characterized,
suggesting underascertainment of cases and the need for further research.
Introduction
Chikungunya virus (CHIKV) is an alphavirus whose recognized global distribution increas-
ingly overlaps that of dengue and the distribution of their shared mosquito vectors, Aedes
aegypti and Aedes albopictus [1]. Clinical reports suggest that CHIKV may have been broadly
distributed by the 1800s, though its similar clinical presentation to Dengue virus (DENV)
makes its historic epidemiology uncertain [2]. Since the first isolation of CHIKV in Tanzania
in 1952–53 [3], large urban outbreaks have been detected in the Indian Ocean region and
Latin America, yielding millions of suspected infections and the novel discovery of autochtho-
nous CHIKV transmission in Mediterranean Europe in 2007 [4–9]. The past decade has wit-
nessed novel reports of CHIKV outbreaks in the Middle East and North Africa (MENA) as
well. However, the present and historic epidemiology of CHIKV in this region remains poorly
characterized.
Over the years, limited surveillance and diagnostic capacity have likely hindered the recog-
nition of CHIKV in the MENA region. Although the earliest possible clinical description of
CHIKV infection known to exist was first recorded in Cairo, Egypt in 1658 [2], it was not until
2011 that the presence of CHIKV was first confirmed (i.e. by viral culture or molecular detec-
tion) in the MENA during an outbreak in Yemen with over 15,000 suspected cases [10]. The
CHIKV lineage responsible for this epidemic was related to the enzoonotic East-Central-South
African (ECSA) Indian Ocean Lineage and was isolated from A. aegypti, a finding that sug-
gested urban cycle transmission [11, 12]. To date, the existence of a sylvatic transmission cycle
has not been reported in the MENA region. Although debilitating and prolonged polyarthral-
gias can be a recognizable hallmark of CHIKV infection [1], the clinical syndrome can be diffi-
cult to distinguish from other mosquito-transmitted febrile illnesses including dengue fever [2,
10, 13], o’nyong’nyong fever [2], yellow fever [14], and malaria [14]. Given the increasing
Chikungunya in the MENA
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global impact of Aedes-transmitted arboviruses and the limited knowledge of urban CHIKV in
the MENA region, we performed a systematic review of the literature to describe the published
evidence pertaining to the epidemiology of CHIKV in the MENA region.
Objectives
The objective of this study was to characterize the epidemiology of urban CHIKV in the
MENA region through a systematic review of published human prevalence and incidence
studies, human outbreaks and reported cases, and studies reporting CHIKV detections and
prevalence/infection rates in Aedes mosquitoes. The original literature search was conducted
in December 2015 and updated in May 2017.
Materials and methods
The materials and methods used for this review are similar to those of a systematic review of
DENV in the MENA region that we conducted in parallel to the current study [15].
Eligibility criteria
The eligibility criteria for this study follows similar criteria that was used for a review of DENV
in the MENA region (Table 1) [15]. In brief, reports containing primary human seropreva-
lence or incidence, outbreaks and reported cases, and CHIKV detections from Aedes mosqui-
toes in the MENA region published in any year were considered eligible for the systematic
review. For incidence studies, those that reported the number of acute infections or serocon-
versions over any time interval, or overall attack rate if assessed during an outbreak, were eligi-
ble. Human CHIKV outbreaks, case series, and case reports in natives and returned travelers
from the MENA region were also sought from the articles retrieved through the search data-
bases using the original search criteria. Outbreak reports were included if at least some of the
reported cases were laboratory-supported CHIKV infection; cases series and case reports were
only included if they were laboratory-supported. We considered any report of CHIKV cases to
constitute an outbreak if the author of the report qualified it as such. As with DENV, there is
currently no consensus on how to define CHIKV outbreaks, so determining whether any
Table 1. Criteria for study inclusion or exclusion.
Study type Inclusion Criteria Exclusion Criteria
Human prevalence
and incidence
publication
characteristics
Full article or abstract published in any year, language, setting,
or human population in the MENA region; any seroconversion
interval for incidence studies or population-based attack rate
editorials, letters to editors, reviews, commentaries, qualitative
studies, basic science research studies, studies conducted in
countries outside the MENA region, studies conducted in
animals
study design Any randomized or non-randomized design Non-empirical research/modelled data
outcomes CHIKV seroprevalence or prevalence of laboratory-confirmed
infection; CHIKV incidence (by any laboratory method)
No human prevalence or incidence measure reported
Human outbreaks Any outbreak defined as such in the report; reports may include
laboratory-confirmed and suspected cases
No laboratory-supported information that CHIKV was the
pathogen
Human case reports
and case series
Any cases reported in MENA natives or in returned travelers
from a MENA country, confirmed by any laboratory method
No laboratory method reported
Virus prevalence in
vectors
Reported CHIKV prevalence in Ae. aegypti or Ae. albopictus
pools (i.e. absolute number of positive pools); estimated
infection rates (minimum/maximum) by any laboratory method
Basic science research studies, virus prevalence or CHIKV
detections in other mosquito species or in non-MENA country
Single virus isolations
in vectors
Any reports of single CHIKV isolates or vRNA detections from
Ae. aegypti or Ae. albopictus obtained by any laboratory method
Mosquito captured in non-MENA country
https://doi.org/10.1371/journal.pntd.0005707.t001
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number of cases represents a significant deviation from baseline transmission is often unclear
[15].
Finally, studies containing CHIKV prevalence in Aedes pools and single CHIKV isolates or
vRNA detections from Aedes were included if they contained a measure of the estimated pro-
portion of CHIKV-infected Ae. aegypti or Ae. albopictus at a given time and setting in the
MENA region. Prevalence studies in animals were noted but excluded from the systematic
review, as our study focused on urban cycle CHIKV mediated by human-mosquito transmis-
sion. Our review covered the 23 countries included in the MENA definitions of the WHO/
EMRO, World Bank, and the Joint United Nations Programme on HIV/AIDS (UNAIDS) for
consistency with our systematic review of DENV in the MENA region as well as our earlier
regional analyses of various infectious diseases such as HIV and other sexually transmitted
infections and Hepatitis C virus [16–19].
Outcomes
For the systematic review, the primary outcomes were CHIKV human seroprevalence, human
CHIKV incidence, human case reports/case series of CHIKV infection in MENA natives and
returned travelers from the MENA region, CHIKV prevalence in Aedes, and single virus iso-
lates of CHIKV in Aedes in the MENA region.
Data sources and search strategy
We conducted a systematic search for CHIKV in the MENA informed by the Cochrane Col-
laboration guidelines [20] and reported our findings using the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) guidelines [21]. The PRISMA checklist is
found in S1 Table and our search criteria in S1 Fig. We searched PubMed (indexed since 1966
and selectively since 1865) and Embase (indexed since 1988) using text and MeSH/Emtree
terms exploded to include all subheadings, as well as the World Health Organization (WHO)
Index Medicus for the Eastern Mediterranean Region, WHO African Index Medicus (both
indexed since 1984), and ProMED-MENA (indexed since 1994) using only the search term
“chikungunya”.
Study selection
The methodology for this section also follows our previous review of DENV [15]. Titles and
abstracts were imported into Endnote (Thompson Reuters, Philadelphia, PA, USA) and were
screened by one author (JH) with potential eligibility determined by consensus with a second
author (NC) when eligibility was unclear. Full texts of potentially relevant records were
retrieved and assessed for eligibility, contacting the author of the report as necessary. Reference
lists of all potentially eligible articles and reviews were also searched. For this study, ‘report’
refers to the document (paper, abstract, or public health record) containing an outcome mea-
sure of interest, while ‘study’ refers to the outcome measure(s) within that report. Hence,
reports could contribute more than one study, though multiple reports of the same study were
counted only once.
Data extraction and synthesis
Data were extracted by one of the authors (JH). Data from reports in English were extracted
from the full texts, while reports in French (n = 1) and German (n = 1) were extracted from
the English abstract and with the help of online language software and French and German
language speakers [22]. There were no records in other languages. Studies were compiled by
Chikungunya in the MENA
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country and organized by year. Prevalence studies were stratified as follows: 1) general preva-
lence studies assessing anti-CHIKV IgG prevalence (e.g. CHIKV exposure) among individuals
not suspected to have acute CHIKV infection, including community members, blood donors,
military, students, and hospitalized patients and outpatients receiving care for non-febrile ill-
nesses, and 2) acute febrile illness studies assessing the prevalence of laboratory-supported
CHIKV infection (i.e. any positive laboratory test suggesting CHIKV infection) in those with
undifferentiated acute febrile illness (AFI) or suspected arbovirus infection (IgG prevalence
measures obtained during the acute phase of illness in these studies are presumed to reflect an
earlier infection). These stratifications were made because of the different study aims and pre-
test probabilities of having laboratory evidence of CHIKV infection in these populations.
Reports were summarized by country and year, along with the sampling method, assay type/
make, sample size, and any data pertaining to alphavirus cross-reactions that was available.
For CHIKV outbreaks, we recorded the year, location, suspected or confirmed vector, and
number of cases as provided in each report. We recorded similar information for case reports/
series and cases in returned travelelers as available. Finally, reports containing CHIKV preva-
lence, infection rates, and single virus isolations in Ae. aegypti and Ae. albopictus, both recog-
nized urban cycle CHIKV vectors, were also sought using the original search criteria. We
recorded the year, location, and methods of collection and laboratory methods, as well as addi-
tional bioecological aspects of the vectors as available. The geographic distribution of all
included human prevalence studies, outbreak reports, and case reports/series were mapped
according to the first-level administrative division (e.g. state, province) in which each event
was recorded (Tableau Software, Seattle, WA, USA).
Risk of bias assessment
The risk of bias (ROB) was assessed for each seroprevalence study based on the Cochrane
approach [20] and by evaluating the precision of the reported measures according to previ-
ously developed methodology [23, 24]. Each CHIKV seroprevalence measure was considered
to have a low, high, or unclear ROB in two domains: sampling methodology and response rate.
The latter was defined as the number of tested individuals divided by the number of persons
invited to participate in the study [25]. ROB was considered low if (1) sampling was probabil-
ity-based (using some form of random selection), and (2) response rate was80%. Studies
with missing information for either of the domains were classified as having unclear ROB for
that specific domain. We did not assess the ROB for the sampling methodology of populations
with acute febrile illness, as these are defined populations presenting to a health facility with
acute infection and no population-based sampling is needed to capture these populations. We
also did not include the laboratory assay characteristics in our risk of bias assessment given
that the epidemiology of antigenically similar alphaviruses (e.g. O’nyong-nyong virus [ONNV],
Sindbis virus [SINV], and Semliki Forest virus [SFV]) in the MENA was also unclear, and nearly
all identified studies utilized in-house assays. Studies were considered to have high precision if
the number of individuals tested was 100. We considered this to be a reasonably sensitive
cutoff for precision given the heterogeneous epidemiology of CHIKV across the region (e.g. a
prevalence of 1% has a 95% CI of 0–3%).
Results
Search results
The selection process based on PRISMA guidelines is illustrated in Fig 1 [21]. Briefly, the
search yielded 262 reports, 35 of which were eligible for inclusion in the study following
screening process and after the addition of 8 reports identified from reference lists and reviews.
Chikungunya in the MENA
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One animal seroprevalence study was excluded, in which anti-CHIKV antibody prevalence of
2.5% was reported in a sample of 157 rodents captured in Pakistan. In this study, all antibodies
were cross-reactive with SINV [26].
Characteristics of included studies
A total of 29 human seroprevalence studies for CHIKV were identified from eligible reports,
62% of which were conducted prior to 1990 (Table 2). Fig 2 illustrates the geographic distribu-
tion of all published CHIKV prevalence studies, outbreaks, and reported cases in the MENA
region. Overall, anti-CHIKV antibodies were reported from 10 of 23 countries in the MENA:
Djibouti, Egypt, Iran, Iraq, Kuwait, Pakistan, Saudi Arabia, Somalia, Sudan, and Yemen. The
Fig 1. PRISMA flow diagram of report selection in the systematic search.
https://doi.org/10.1371/journal.pntd.0005707.g001
Chikungunya in the MENA
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Table 2. Human prevalence studies for Chikungunya virus in the Middle East and North Africa (n = 29).
Country,
Ref.
Year(s)
of
study*
City or
Governorate
Setting; population
(age range, years)
Sampling Assay
type†
Assay
make
Sample
size
Prevalence Additional testing &
Comments
Djibouti
(n = 4)
Salah [27] 1987 Djibouti City Military; healthy
soldiers
Conv. IIFT In-house 50 0% no additional testing
performed
Randa Rural community;
general pop.
Conv. IIFT In-house 69 0% no additional testing
performed
Djibouti City Hospital; AFI patients Conv. IIFT In-house 41 2.4% The single IIFT+ subject
was a native of Ethiopia
and was cross-reactive
with SINV
Andayi [31] 2010–
11
Djibouti City Household survey;
general pop.(<1–100)
SRS ELISA In-house 914 2.6% 95.9% (23/24) ELISA
+ were VNT+
Egypt (n = 2)
Darwish [41] 1974* Multiple n/s; general pop. (<1–
70)
n/s HI In-house 231 0% 0% were SFV+; 16.8%
were SINV+
Darwish [37] 1985 Cairo Hospital; AFI patients
(>10)
Conv. HI In-house 55 5.5% 0% (0/55) were
convalescent +; 0% were
SINV+
Iran (n = 2)
Saidi [28] 1970 Multiple n/s n/s HI In-house 394 22.1% no additional testing
performed
Saidi [42] 1970–
71
Caspian
region
Community; children
(1–6)
Conv. HI In-house 100 0% 0% were SINV+
Iraq (n = 1)
Barakat [43] 2012–
13
Nasiriyah Community; healthy
medical staff, blood
donors, students, non-
AFI patients (10–82)
n/s IIFT In-house 399 0.5% 2 of 4 ambiguous CHIKV
+ samples were VNT+;
2% (8/399) of CHIKV
+ were SINV+; 6/8 SINV
+ were VNT+; all SINV
+ and CHIKV+ samples
were negative for SFV
by VNT
Kuwait
(n = 2)
Ibrahim [29] 1966–
68
Multiple Multiple; blood donors,
non-AFI patients,
children (1–60)
Conv. HI In-house 627 1.4% 78% (7/9) CHIKV
+ samples were cross-
reactive to SINV and
SFV; 4.5% (28/627)
were SINV+; 2.6% (16/
627) were SFV+
Al-Nakib [30] 1979–
82
Jabriya Hospital; non-AFI
patients (0–60+)
SRS HI In-house 502 0.4% 100% (2/2) CHIKV
+ samples were cross-
reactive with SINV
Pakistan
(n = 2)
Darwish [26] 1983* Karachi Hospital; patients Conv. CF In-house 43 2.3% 2.3% were SINV+;
possible CHIKV cross-
reaction with SINV
Afzal [44] 2011 Lahore Hospital; AFI patients
(<12)
Conv ELISA n/s 75 4% no additional testing
performed
Somalia
(n = 1)
(Continued )
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Table 2. (Continued)
Country,
Ref.
Year(s)
of
study*
City or
Governorate
Setting; population
(age range, years)
Sampling Assay
type†
Assay
make
Sample
size
Prevalence Additional testing &
Comments
Botros [38] 1987 Hargeysa Refugee camp; AFI
patients
Conv. HI In-house 28 0.0% 0% (0/10) convalescent
samples tested were HI
+; 0% (0/28) were HI+ for
SINV
Sudan
(n = 11)
Salim [32] 1973* Sennar Community and
clinical setting; general
pop. and non-AFI
patients (<1–40+)
Conv. VNT In-house 62 12.9% 23% (11/48) were also
VNT+ for ONNV
Omer [33] 1976 Gezira State Rural community;
general pop. (5–40+)
Conv. HI In-house 109 24.8% 0.9% (1/109) were also
HI+ to SINV; 8.2% (9/
109) were VNT+ for
CHIKV
Woodruff
[45]
1986 Juba Hospital; patients with
history of fever within
past 6 months and AFI
patients (1–85)
Conv. HI In-house 130 23.1% 3.1% (4/130) were HI
+ for SINV; 2.3% (3/130)
were HI+ for SFV; no
observed cross-reaction
between CHIKV and
SINV or SFV; 1
observed cross-reaction
between SINV and SFV
McCarthy
[46]
1988 Khartoum Clinical setting; non-
AFI patients
Conv. ELISA In-house 100 11% 1/100 (1%) were IgM+
Khartoum Clinical setting; AFI
patients (1–89)
Conv. ELISA In-house 196 10% 1/200 (0.5%) were IgM+
Watts [47] 1989 Northern state Clinical setting; AFI
patients (11–70)
Conv. ELISA In-house 185 12.0% no additional testing
performed
Farnon [14] 2005 Kortalla Community; general
pop. (0–44+)
SSCS ELISA In-house 87 43% 1% (1/87) was CHIKV
IgM+; 7.9% (3/38)
CHIKV+ samples were
SINV+
Gould [48] 2005 South
Kordofan
Clinical setting;
suspected YF patients
(n = 3), severe illness
(n = 8), AFI patients
(n = 7), healthy
(n = 16)
Conv. ELISA
IgM
In-house 34 23.5% no additional testing
performed
Adam [34] 2012–
13
Eastern and
Central Sudan
Clinical setting; AFI
patients (<15–45+))
Conv. ELISA Euroimmun 379 1.8% All ELISA+ were also IFA
+ and VNT+
Baudin [49] 2011–
12
Port Sudan Hospital; pregnant
women with fever
Conv. qRT-PCR In-house 130 30% 8 of 39 CHIKV+ patients
were also positive for Rfit
Valley Fever virus by
PCR or IgM ELISA
Enkhtsetseg
[50]
2012–
13
South Sudan Military; military
seroconversion study
over ~6 month period
Conv. HI In-house 632 0% no additional testing was
performed
Tunisia
(n = 1)
Nabli [51] 1970* Multiple n/s; children Conv. HI In-house 100 0% 0.2% (3/1406) were HI
+ for SINV
Yemen
(n = 3)
(Continued )
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median seroprevalence measures among general populations was 1.0% (range 0–43%), and
9.8% (range 0–30%) among populations with acute febrile illness. Sudan reported both the
highest number of studies (n = 11) and the highest seroprevalence measures overall (median
12.9%, range 0–43%). Ninety-three percent of all studies utilized in-house assays; 82% of all
studies that were conducted after 1990 (n = 11) utilized ELISA and/or RT-PCR (or RT-qPCR);
56% (10/18) of studies prior to 1990 utilized hemagglutinin inhibition (HI) assays. Serologic
Table 2. (Continued)
Country,
Ref.
Year(s)
of
study*
City or
Governorate
Setting; population
(age range, years)
Sampling Assay
type†
Assay
make
Sample
size
Prevalence Additional testing &
Comments
Madani [35] 2010 Hadramout Clinical settings;
suspected viral
hemorrhagic fever (3–
75)
Conv. RT-PCR In-house 222 0% no additional testing
performed
Malik [10] 2010–
11
Al-Hudaydah Clinical setting; AFI
patients (0–45+)
Conv. ELISA
IgM
In-house 136 28% 40% (54/136) were RT-
qPCR+; 22% (30/136)
were cell culture +
Rezza [36] 2012 Al Hudaydah Hospitals; AFI patients
with ‘dengue-like’
illness (1–60)
Conv ELISA
IgM
NovaLisa 400 9.8% 2.8% (11/400) were RT-
qPCR+; 9.4% (33/351
negative IgM/PCR) were
IgG+
* Indicates year of publication when year(s) of data collection not available in report.
† All serologic assays were IgG unless otherwise stated.
Abbreviations: AFI, acute febrile illness patients; CF, complement fixation; Conv, convenience; ELISA, enzyme-linked immunosorbent assay; HI,
hemagglutinin inhibition; IFA, indirect fluorescent antibody, IIFT, indirect immunofluorescence test; n/s, not specified; ONNV, O’nyong-nyong virus; pop.,
population; PCR, polymerase chain reaction; RT-qPCR, quantitative reverse transcription PCR; SFV, Semliki Forest virus; SINV, Sindbis virus; SRS, simple
random sampling; SSCS, single stage cluster sampling; VNT, viral neutralization test
Assay Abbreviation: NovaLisa (Dietzenbach, Germany)
https://doi.org/10.1371/journal.pntd.0005707.t002
Fig 2. Geographic distribution of human prevalence studies and reported outbreaks and cases for Chikungunya
virus in the Middle East and North Africa.
https://doi.org/10.1371/journal.pntd.0005707.g002
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cross-reactions with related alphaviruses (e.g. ONNV, SINV, and SFV) or travel-acquired
infections were observed or could not be excluded in some studies from Djibouti [27], Iran
[28], Kuwait [29, 30], and Pakistan [26]. Viral neutralization testing was performed in a total
of five studies from Djibouti [31], Iraq [32, 33], and Sudan [32–34]. Among acute febrile illness
studies, the prevalence of laboratory-supported CHIKV infection was also highest in Sudan,
with anti-CHIKV antibody prevalence by HI or ELISA ranging from 1.8% to 30%. In Yemen,
0% of 222 cases of undifferentiated AFI were positive for CHIKV in the eastern coastal city of
Al-Mukalla in June 2010 [35]. Four months later, however, an outbreak of CHIKV was
detected in the western coastal governorate of Al-Hudaydah, Yemen, and two studies demon-
strated 9.8% and 28% ELISA IgM seroprevalence among subjects with undifferentiated AFI
[10, 36].
Convalescent sera results were reported in two AFI studies, neither of which was positive as
indicated by a four-fold rise in antibody titers [37, 38]. One study reporting detection of
CHIKV in mosquito pools was identified in our search, in which CHIKV was detected by RT-
qPCR in 26.6% of 11 pools of 30 Ae. aegypti mosquitoes that were collected at an Eritrean refu-
gee camp in Al Hudaydah, Yemen during the aforementioned CHIKV outbreak [39]. In this
study, mosquitoes were collected by BG-sentinelTM traps, Knock-down pyrethroid spray, and
indoor aspirations from houses of recently reported cases, and larvae were inspected in all pos-
sible containers per house or inhabited premises. The total container index of the sampled
sites was 53.8, Breteau index was 100, and house index was 57. Ae. aegypti adult female mini-
mum and maximum infection rates were 20% and 72%, respectively. There were no published
reports of single CHIKV isolations from mosquitoes or population-based human incidence
identified in our search. However, during the 2012 CHIKV outbreak in southern Yemen, one
study reported an overall CHIKV attack rate of 7.5 per 1,000 people, ranging from 5.3 among
children 0–4 years of age to 12.2 among adults 45 years [40].
Precision and risk of bias assessment results
The quality assessment for each prevalence study is found in Table 3. Overall, 66% (19/29) of
studies contained high precision as defined by a sample size of100 subjects. For the risk of
bias assessment, response rates were80% in 14% (4/29) of studies, <80% in 3% (1/29) of
studies, and not reported in 83% (24/29) of studies. Among general seroprevalence studies,
some form of probability sampling (i.e. low ROB) was reported in 31% (5/16) of studies, non-
probability sampling (e.g. high ROB) in 31% (5/16) of studies, and unclear sampling methods
in 38% (6/16) of studies.
A total of four CHIKV outbreaks, three case reports/series, and one report of CHIKV in
returned travelers, were identified through the search databases (Table 4) and were mapped
along with the geographic distribution of prevalence studies (Fig 2). Outbreaks were reported
from Djibouti, Sudan, Pakistan, and Yemen. In most cases, the vector was suspected to be Ae.
aegypti given its known occurrence in the affected countries, but was only confirmed as such
in the 2011–2012 outbreak in Yemen [10].
Discussion
Our review examines the epidemiology of urban CHIKV in the MENA region by summarizing
published human prevalence and incidence studies, outbreaks, reported cases, and reports of
CHIKV detected in Aedes mosquitoes. Serologic and outbreak evidence of CHIKV transmis-
sion has been identified in the countries surrounding the Red Sea (Djibouti, Egypt, Saudi
Arabia, Somalia, Sudan, and Yemen) and Pakistan. This distribution overlaps the known
distribution of DENV in the MENA region [15]. No outbreaks, cases of autochthonous
Chikungunya in the MENA
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005707 June 26, 2017 10 / 19
transmission, or human seroprevalence studies were reported from 13 of 23 countries in the
MENA region, while a single seroprevalence studies in Tunisia [51] did not identify anti-
Table 3. Precision and risk of bias assessment for Chikungunya virus prevalence measures in the Middle East and North Africa.
Country, Ref. Year(s) of study Population Risk of Bias Assessment Precision
Sampling* Response rate
Djibouti
Salah [27] 1987 Healthy soldiers High ROB Unclear ROB Low
General population High ROB Unclear ROB Low
1987 AFI patients n/a Unclear ROB Low
Andayi [31] 2010–11 General population Low ROB High ROB High
Egypt
Darwish [41] 1974 General population Unclear ROB Unclear ROB High
Darwish [37] 1985 AFI patients n/a Unclear ROB Low
Iran
Saidi [28] 1970 n/s Unclear ROB Unclear ROB High
Saidi [42] 1970–71 Children Low ROB Unclear ROB High
Iraq
Barakat [43] 2012–13 General population, blood donors, non-AFI patients Unclear ROB Unclear ROB High
Kuwait
Ibrahim [29] 1966–68 Blood donors, non-AFI patients, children Low ROB Unclear ROB High
Al-Nakib [30] 1979–82 non-AFI patients Low ROB Unclear ROB High
Pakistan
Darwish [26] 1983 Hospital patients Unclear ROB Unclear ROB Low
Afzal [44] 2011 AFI patients n/a Unclear ROB Low
Somalia
Botros [38] 1987 AFI patients n/a Unclear ROB Low
Sudan
Salim [32] 1973* General population and non-AFI patients Unclear ROB Unclear ROB Low
Omer [33] 1976 General population High ROB Unclear ROB High
Woodruff [45] 1986 AFI patients n/a Unclear ROB High
McCarthy [46] 1988 Non-AFI patients High ROB Unclear ROB High
AFI patients n/a Low ROB High
Watts [47] 1989 AFI patients n/a Unclear ROB High
Farnon [14] 2005 General population Low ROB Unclear ROB Low
Gould [48] 2005 AFI patients n/a Low ROB Low
Adam [34] 2013–13 AFI patients n/a Unclear ROB High
Baudin [49] 2011–12 Pregnant women with AFI n/a Unclear ROB High
Enkhtsetseg [50] 2012–13 Military High ROB Unclear ROB High
Tunisia
Nabil [51] 1970 Children Unclear ROB Unclear ROB High
Yemen
Madani [35] 2010 Suspected viral hemorrhagic fever n/a Low ROB High
Malik [10] 2010–11 AFI patients n/a Low ROB High
Rezza [36] 2012 Patients with dengue-like illness n/a Unclear ROB High
* Since the populations of acute febrile illness or suspected arbovirus infection are defined as populations presenting to a health facility with acute infection,
no population-based sampling is needed to capture these populations and they are denoted ‘n/a’ in the sampling column.
Abbreviation: AFI, acute febrile illness
https://doi.org/10.1371/journal.pntd.0005707.t003
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CHIKV antibodies in the populations tested. Given increasing reports of Ae. aegypti and Ae.
albopictus occurrence and DENV transmission in the MENA over recent years, the possibility
of unrecognized CHIKV transmission or cross-border spread of CHIKV to these countries
merits consideration.
As the bulk of epidemiologic evidence for CHIKV is serologic, the genetic diversity of
CHIKV circulating in the MENA is largely unknown. To date, the only published CHIKV
strain from the MENA comes from the 2011 Yemen outbreak [10]. This virus was found to be
similar to the East-Central-South African (ECSA) Indian Ocean Lineage that was responsible
for the 2004–2006 Indian Ocean epidemic [11, 12] and subsequent urban outbreaks in South-
east Asia, Italy, and France [57]. Still, CHIKV lineages may be diverse within North Africa and
distinct from other regions in Africa. Distinct enzootic / epidemic ECSA lineages may be cir-
culating in Sudan, for example, given the repeated detection of anti-CHIKV antibodies in
Sudanese populations since the 1970s [32, 33], Sudan’s proximity to East Africa (where
CHIKV has long been endemic), and the sylvatic habitats in Sudan’s Nuba Mountain region
where several yellow fever outbreaks may have emerged from in the past [14, 32, 58–60]. Con-
tiguous spread of CHIKV from India to Pakistan is similarly plausible, as is import-related out-
breaks from more remote regions, such as from South Asia to the Arabian Peninsula or from
Mediterranean Europe to North Africa.
A variety of ecologic and social risk factors may be driving the spread of Aedes in the
MENA, which we describe in detail in our recent publication on DENV in the MENA [15].
These factors include increasing urbanization [61], use of open water storage that encourages
Ae. aegypti breeding [39, 62], armed conflict and poverty [63, 64], and extensive inter- and
intra-regional trade and migration [12, 65]. The 2011 CHIKV outbreak in Yemen illustrates
several vulnerabilities to Aedes-borne arboviruses potentially faced by the MENA [10]. Heavy
travel and commerce through the port city of Al Hudaydah was thought to have led to CHIKV
Table 4. Summary of reported outbreaks, case series, case reports, and cases in travelers for Chikungunya virus in the Middle East and North
Africa.
Country,
Year
City or
Governorate
Description Ref.
Djibouti
2011 Djibouti City Chikungunya outbreak reported was concurrent with 2011 outbreak in Yemen; Aedes aegypti was the
suspected vector.
[31]
Pakistan
2016–17 Karachi A total of 2,267 reported cases during an outbreak from December 2016 to May 2017. Aedes aegypti was the
suspected vector.
[52]
Saudi Arabia
2011 Jeddah First autochthonous case of chikungunya detected by qRT-PCR in Saudi Arabia; unconfirmed vector. [53]
Somalia
2016 Mogadishu Two travelers returning to Italy from Mogadishu, Somalia. For both patients, testing was positive by CHIKV IFA
IgG and IgM (Euroimmun), Anti-CHIKV IgM ELISA (Euroimmun), and PRNT.
[54]
2016 Mogadishu 11 cases were confirmed by RT-PCR, representing the first reports of human CHIKV infection by Somalia;
unconfirmed vector.
[55]
Sudan
2005 South Kordofan Concurrent chikungunya transmission detected during yellow fever outbreak; Aedes aegypti was the suspected
vector.
[48]
2014 Not specified 16 cases were reportd from Sudan in 2014; unconfirmed vector [55]
2015 Darfur 4 laboratory-confirmed cases were reported from Sudan in 2015; unconfirmed vector [56]
Yemen
2011–12 Al Hudaydah, Lahj Over 15,000 suspected cases during an outbreak; Aedes aegypti was the proven vector. [10]
https://doi.org/10.1371/journal.pntd.0005707.t004
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introduction, possibly from North African port cities along the Red Sea coast. A CHIKV out-
break was reported in Djibouti City [31] the same year of the Yemen outbreak, and the follow-
ing year, autochthonous transmission of CHIKV was noted in Saudi Arabia [53]. Similar
transmission patterns have been cited as risk for DENV infection spread in the Red Sea sub-
region [10, 12, 27, 66, 67]. High rainfall in Al Hudaydah months prior to the outbreak may
have also amplified the Aedes population to a level capable of sustaining an outbreak. The out-
break was not detected until nearly 16 weeks after its suspected onset, in part attributable to a
lack of surveillance and case detection, and initial misrecognition of the disease as DENV in a
known dengue-endemic area [10]. Prompter initiation of vector control measures may have
forestalled the amplification of the outbreak over the following months.
Serologic cross-reactions for alphaviruses like CHIKV are well documented and represent
an important limitation of epidemiologic studies which rely on serology in the absence of con-
firmatory neutralization tests. Serologic evidence of CHIKV in the absence of neutralization
tests must be interpreted with caution, as such results may represent cross-reactions between
CHIKV and another alphavirus (e.g. SINV, ONNV, or SFV), co-cicrulation of both viruses,
cross neutralization between both viriuses, or the presence of another antigenically-related
virus that induces cross-neutralizing antibodies to both alphaviruses [68]. These alphaviruses
may have similar clinical presentations and geographic distributions in the MENA region,
while the increase in international travel, intensification of trade, and the spread of potential
vectors as a result of climate change may further drive overlapping endemicity [69]. In our
review, serologic cross-reactions were reported in 9 of 14 seroprevalence studies, most com-
monly due to SINV, another Old World alphavirus identified in the MENA whose epidemio-
logic impact is also poorly understood [70]. Like West Nile Virus, SINV may be broadly
distributed in the MENA given its enzoonotic transmission cycle involving migratory avian
hosts and ubiquitous Culex mosquitoes [71–73]. In a study by Ibrahim et al. in Kuwait, 78%
(7/9) CHIKV positive samples were cross-reactive to SINV and SFV by HI testing, while cross-
reactivity between SINV and SFV occurred in an additional 9 of 21 SINV-reactive sera [39]. In
a second study from Kuwait, all CHIKV positive samples were cross-reactive to SINV [30].
This evidence does not confirm CHIKV circulation in Kuwait. Antibodies against ONNV,
another Old World alphavirus whose distribution is likely underreported, were only sought
(and confirmed by VNT) in one study from Sudan conducted in 1973 [32]. Yet although the
distribution of ONNV in the MENA region requires further research, it is unlikely that the
serologic studies reporting CHIKV are primarily detecting ONNV. A one-way antigenic
cross-reactivity has been described between CHIKV and ONNV, in which antibodies against
CHIKV neutralize ONNV but anti-ONNV antibodies do not recognize CHIKV [74, 75]. Fur-
ther assurance of the detection of CHIKV antibodies is found in the study by Andayi et al. in
Djibouti, in which a non-inactivated viral antigen was utilized for ELISA testing (allowing for
selection of more specific anti-CHIKV antibodies) and results were confirmed by seroneutrali-
zation [31].
CHIKV may continue to spread in the MENA region as it has in other regions. Surveillance
programs and clinicians should maintain alertness for CHIKV, particularly in dengue-
endemic areas, given the overlapping clinical presentation and geographic distribution of both
pathogens. Addressing this challenge will require multiplexed serologic and molecular diag-
nostics able to simultaneously detect and discriminate between CHIKV and other pathogens
with overlapping clinical manifestations, such as DENV, malaria, ONNV, Yellow fever virus,
and Zika virus [2, 10, 13, 14, 48, 76–80]. Such diagnostics could also circumvent the issue of
cross-reactivity and the frequent unavailability of convalescent serology. However, molecular
diagnostics are limited by the presence of viral RNA or antigen for a limited duration during
acute infection. Studies to understand the distribution of Aedes and infection rates in Aedes in
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the MENA are also important, as they can inform our understanding of transmission dynam-
ics which is useful for vector control strategies and predicting future transmission risk [71–
73]. Our review identified only one published study of CHIKV isolated from Aedes in the
region [39], depite the published occurrence of Ae. aegypti and Ae. albopictus in 11 and 7
MENA countries, respectively [15].
Our study was limited by its use of select databases of peer-reviewed literature with the pos-
sible exclusion of some grey literature which may have provided additional data (the African
Index Medicus and Index Medicus for the Eastern Mediterranean Region databases do index
grey literature). Reports from public health laboratories in each country may also have pro-
vided additional data, though we chose to focus our review on published literature that would
be available to the broader academic community in the region. In addition, although we did
not impose any publication year restrictions in our search, Embase and the regional databases
began indexing articles after 1980, so earlier publications may have been overlooked during
our search. PubMed began indexing articles prior to the discovery of CHIKV in 1952–53, how-
ever. The urban cycle focus of CHIKV epidemiology must also be underscored in our manu-
script, as we did not include seroprevalence studies in animals (i.e. sylvatic cycle) in our review
criteria. Still, only one seroprevalence study in animals was identified in our search. It is likely
that our study generally reflects the available seroprevalence literature concerning CHIKV in
the MENA, as we identified no mention of sylvatic cycle CHIKV in the MENA over the course
of our review. CHIKV may primarily exist in a human-peridomestic mosquito cycle in the
MENA, as it existis in Asia [6], though sylvatic cycle CHIKV is known to exist elsewhere in
Africa [81]. Non-publication of studies with small or zero effect size may also have biased the
distribution of studies identified in our review. The absence of confirmatory neutralization
tests in many studies is an additional limitation, along with the lack of convalescent serum
tests to demonstrate antibody titer kinetics in acute infections, both of which would reduce the
likelihood of cross-reaction. Indeed, serologic cross-reactions may have overestimated CHIKV
seroprevalence in multiple studies. Finally, given the small number of studies and sparse distri-
bution and content of available studies, we did not perform a meta-analysis or explore bias in
overall outcome measures through a funnel plot or Egger test nor did we exclude studies based
on the risk of bias assessment. This resulted in the inclusion of studies of varying methodologi-
cal rigor and scientific quality.
Conclusions
In the MENA region, published reports suggest endemic circulation of CHIKV in the Red Sea
Region and Pakistan, similar to the known geographic distribution of DENV. Published epide-
miologic studies are lacking in many sub-regions, including some Aedes and DENV endemic
areas, further suggesting underrecognition of CHIKV in the MENA. These findings articulate
the need for further research to understand the epidemiology of CHIKV in the MENA.
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